You are here

JAK inhibitors

Ajax, aiming for a better JAK drug, raises $95M to begin first tests

BioPharma Dive

Tue, 05/14/24 - 11:37 am

Ajax Therapeutics

Aclaris finishes enrolment in atopic dermatitis Phase IIb trial of ATI-1777

Clinical Trials Arena

Wed, 10/4/23 - 11:10 am

atopic dermatitis

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

Endpoints

Tue, 03/21/23 - 10:06 am

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

Endpoints

Tue, 03/1/22 - 10:35 am

Bristol Myers Squibb

Novartis JAKs in rival to Incyte's topical eczema drug after seeing clinical data

Fierce Biotech

Wed, 02/2/22 - 10:59 am

atopic dermatitis

What to Make of the FDA's Latest Warning to AbbVie and Pfizer

Motley Fool

Sat, 12/18/21 - 10:56 pm

Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change

Endpoints

Wed, 12/15/21 - 10:52 am

Eli Lilly touts long-term safety data for Olumiant amid classwide scrutiny on JAK meds

Fierce Pharma

Wed, 11/10/21 - 09:39 pm

AbbVie's stock and next megablockbuster take hits following new JAK warnings from FDA

Endpoints

Wed, 09/1/21 - 11:16 pm

Can Pfizer Seize Share in This Multibillion-Dollar Market?

Motley Fool

Thu, 08/12/21 - 12:09 am

Incyte the latest to fall victim to JAK scrutiny as FDA pushes back Jakafi review in GVHD

Fierce Pharma

Tue, 06/8/21 - 09:42 pm

Series of JAK inhibitor delays may signal an upcoming FDA adcomm

Endpoints

Thu, 04/8/21 - 11:10 am

FDA pushes eczema decision for Eli Lilly's Olumiant, Pfizer's abrocitinib back 3 months — raising more questions for the JAK class

Endpoints

Wed, 04/7/21 - 10:30 am

AI uncovers Eli Lilly's rheumatoid arthritis drug Olumiant as potential Alzheimer's treatment

Fierce Biotech

Mon, 03/8/21 - 10:42 am

artificial intelligence

Alzheimer's disease

Kinaset launches with $40M and a JAK inhibitor from Vectura's old pipeline

Endpoints

Mon, 11/30/20 - 10:20 am

Kinaset Therapeutics

Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib

Endpoints

Wed, 11/11/20 - 11:04 am

atopic dermatitis

clinical trials

Pfizer Strikes JAK Inhibitor Deal Worth Up to $250 Million With Theravance

BioSpace

Mon, 12/23/19 - 11:52 pm

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

Fierce Pharma

Fri, 10/11/19 - 11:53 am

rheumatoid arthritis

Chasing AbbVie, Gilead files for approval of filgotinib in Japan

Fierce Biotech

Tue, 10/8/19 - 09:40 am

Gilead Sciences

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

Fierce Pharma

Wed, 10/2/19 - 11:53 am

rheumatoid arthritis

Pages